摘要
目的:观察替吉奥胶囊对PS=2-3老年晚期胃癌的治疗疗效及不良反应。方法:采用替吉奥治疗30例PS=2-3老年晚期进展期胃癌患者,对比16例最佳支持治疗患者,化疗2周期后评定疗效,并随访两组患者1年生存状况。结果:治疗组30例中28例可评价疗效和不良反应,治疗组和对照组的近期有效率分别为60.7%和43.8%(P<0.05),1年生存率分别为57.1%和50.0%(P>0.05)。两组PS评分变化无统计学差异,治疗组不良反应轻微,患者能耐受。结论:单药替吉奥方案是疗效较好的治疗PS=2-3老年晚期胃癌的化疗方案,不良反应轻,患者易于耐受。
Objective:To observe the efficacy and toxicity of S-1 for elderly advanced gastric cancer(AGC) in PS=2-3.Methodes: Thirty patients with elderly AGC in PS=2-3 in trial group were evaluated for effect with S-1 after 2 cycles and followed up for 1 year survival status compared with 16 patients in control group.Results: Of 30 patients in trial group,28 were evaluated for effect and safety.The overall response rates were 60.7% and 43.8%(P0.05),1 year survival rates were 57.1% and 50.0%(P0.05) in trial and control groups,respectively.It was not significant in the improvement rate of PS score between trial and control group,and there was not greatly side reaction in trial group.Conclusion: The oral administration of S-1 is a active regimen and toxicity profile is favourable for elderly AGC in PS=2-3.
出处
《现代肿瘤医学》
CAS
2011年第10期2047-2049,共3页
Journal of Modern Oncology
关键词
晚期胃癌
老年
替吉奥
advanced gastric cancer
aged
tegafur
oxonic acid